Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2410020 | 0.85 | USP30 (0.42) | HSD17B10NR1H2NR1H3 | |
| SCHEMBL4916393 | 0.85 | USP30 (0.42) | HSD17B10NR1H2NR1H3 | |
| SCHEMBL4916392 | 0.85 | USP30 (0.42) | HSD17B10NR1H2NR1H3 | |
| SCHEMBL14224498 | 0.82 | HSD17B10 (0.45) | SMN1; SMN2HSD17B10NR1H2NR1H3HPGD | |
| SCHEMBL254261 | 0.82 | HSD17B10 (0.45) | SMN1; SMN2HSD17B10NR1H2NR1H3HPGD | |
| SCHEMBL14224497 | 0.82 | HSD17B10 (0.45) | SMN1; SMN2HSD17B10NR1H2NR1H3HPGD | |
| SCHEMBL25543590 | 0.82 | CHRM2 (0.46) | USP2SMN1; SMN2HSD17B10NR1H2NR1H3 | |
| SCHEMBL30269278 | 0.82 | CHRM2 (0.46) | USP2SMN1; SMN2HSD17B10NR1H2NR1H3 | |
| SCHEMBL14820103 | 0.82 | NR1H2 (0.41) | USP2SMN1; SMN2NR1H2NR1H3CHRM2 | |
| SCHEMBL30847117 | 0.82 | NR1H2 (0.42) | HSD17B10NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6828316-B2 | Antiallergens | KOWA CO., LTD. (JP) | 2004-12-07 | — | — | US | disclosed |
| US-20020042414-A1 | Diamide compound and medicine containing the same | KOWA CO., LTD. (JP) | 2002-04-11 | — | — | US | disclosed |
| US-6340682-B1 | FOR THERAPY OF ALLERGIC IMMUNOLOGICAL DISEASE IS SELECTED FROM ASTHMA, ALLERGIC RHINITIS, INFLAMMATORY LARGE BOWEL DISEASE OR CONTACT DERMATITIS | KOWA CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-0926138-A1 | DIAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | KOWA CO. LTD. (JP) | 1999-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042414-A1 | Diamide compound and medicine containing the same | HRH4, HRH2, HRH1 | USP2 1294/4885SMN1; SMN2 4780/4885HSD17B10 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.